Citations

Showing 10 of 108152 citations.

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Fong, Lawrence , Morris, Michael J. , Sartor, Oliver , Higano, Celestia S. , Pagliaro, Lance C. , Alva, Ajjai , Appleman, Leonard J. , Tan, Winston , Vaishampayan, Ulka N. , Porcu, Raphaelle, Tayama, Darren, Kadel, Edward E. , Yuen, Kobe , Datye, Asim, Armstrong, Andrew J. , Petrylak, Daniel P. , Sartor, A Oliver , Morris, Michael J , Vaishampayan, Ulka , Armstrong, Andrew J , Appleman, Leonard

Mayo Clinic

Clinical Cancer Research | June 9, 2021 | Volume: 27 | Issue: 17 | Pages: 4746-4756

10.1158/1078-0432.ccr-21-0063 | PMID 34108181 Get It

Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti–PD-L1) + radium-223 dichloride (radium-223) in men with mCRPC. Patients and Methods: This phase Ib study evaluated atezolizumab + radium-223 in men with mCRPC and bone and lymph node and/or visceral metastases that progressed after androgen pathway inhibitor treatment. Following safety assessment of concurrent dosing, 45 men were randomized 1:1:1 to concurrent or one of two staggered dosing schedules with either agent introduced one cycle before the other. This was followed by a safety–efficacy expansion cohort (randomized 1:1:1). The primary endpoints were safety and objective response rate (ORR) by RECIST 1.1. Secondary endpoints included radiographic progression-free survival (rPFS), PSA responses, and overall survival (OS). Results: As of October 4, 2019, 44 of 45 men were evaluable. All 44 had ≥1 all-cause adverse event (AE); 23 (52.3%) had a grade 3/4 AE. Fifteen (34.1%) grade 3/4 and 3 (6.8%) grade 5 AEs were related to atezolizumab; none were related to radium-223. Confirmed ORR was 6.8% [95% confidence interval (CI), 1.4–18.7], median rPFS was 3.0 months (95% CI, 2.8–4.6), median PSA progression was 3.0 months (95% CI, 2.8–3.3), and median OS was 16.3 months (95% CI, 10.9–22.3). Conclusions: This phase Ib study demonstrated that atezolizumab + radium-223, regardless of administration schedule, had greater toxicity than either drug alone, with no clear evidence of additional clinical benefit for patients with mCRPC and bone and lymph node and/or visceral metastases.
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
Carter, Jodi M. , Polley, Mei‐Yin C. , Leon‐Ferre, Roberto A. , Thompson, Kevin J. , Wang, Xue , Ma, Yaohua , Zahrieh, David , Kachergus, Jennifer M., Solanki, Malvika , Liu, Minetta C. , Thompson, E. Aubrey , Sinnwell, Jason P , Thompson, Kevin J , Boughey, JC , Liu, Minetta , Ingle, J , Goetz, Matthew P , Carter, Jodi , Sinnwell, Jason P. , Boughey, Judy C. , Ingle, James N. , Kalari, Krishna R. , Couch, Fergus J. , Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | June 9, 2021 | Volume: 27 | Issue: 20 | Pages: 5628-5637

10.1158/1078-0432.ccr-21-0343 | PMID 34108182 Get It

Abstract Purpose: Programmed death ligand 1 [PD-(L)1]-targeted therapies have shown modest survival benefit in triple-negative breast cancer (TNBC). PD-L1+ microenvironments in TNBC are not well characterized and may inform combinatorial immune therapies. Herein, we characterized clinicopathologic features, RNA-based immune signatures, and spatially defined protein-based tumor–immune microenvironments (TIME) in early-stage PD-L1+ and PD-L1− TNBC. Experimental Design: From a large cohort of chemotherapy-naïve TNBC, clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME (Nanostring GeoMX) were identified in subsets of PD-L1+ and PD-L1− TNBC, as defined by FDA-approved PD-L1 companion assays. Results: 228 of 499 (46%) TNBC were PD-L1+ (SP142: ≥1% immune cells-positive). Using PD-L1 22C3, 46% had combined positive score (CPS) ≥ 1 and 16% had CPS ≥10. PD-L1+ TNBC were higher grade with higher tumor-infiltrating lymphocytes (TIL; P < 0.05). PD-L1 was not associated with improved survival following adjustment for TILs and other variables. RNA profiles of PD-L1+ TNBC had increased dendritic cell, macrophage, and T/B cell subset features; and decreased myeloid-derived suppressor cells. PD-L1+ stromal and intraepithelial TIMEs were highly enriched in IDO-1, HLA-DR, CD40, and CD163 compared with PD-L1-TIME, with spatially specific alterations in CTLA-4, Stimulator of Interferon Genes (STING), and fibronectin. Macrophage- and antigen presentation–related proteins correlated most strongly with PD-L1 protein. Conclusions: In this early-stage TNBC cohort, nearly 50% were PD-L1+ (SP142 companion assay) while 16% were PD-L1+ with the 22C3 companion assay. PD-L1+ TNBC had specific myeloid-derived and lymphoid features. Spatially defined PD-L1+ TIME were enriched in several clinically actionable immune proteins. These data may inform future studies on combinatorial immunotherapies for patients with PD-L1+ TNBC. See related commentary by Symmans, p. 5446
What gastroenterologists should know about SARS–CoV 2 vaccine: World Endoscopy Organization perspective
Spadaccini, Marco , Canziani, Lorenzo Maria , Aghemo, Alessio , Lleò, Ana , Maselli, Roberta , Carrara, Silvia , Fugazza, Alessandro , Pellegatta, Gaia , Galtieri, P.A. , Hassan, Cesare , Greenwald, David A. , Pochapin, Mark , Wallace, Michael B. , Röesch, Thomas, Raju, Gottumukkala S. , Repici, Alessandro , Canziani, Lorenzo , Fugazza, Alessandro , Spadaccini, Marco , Hassan, Cesare , Wallace, Michael B , Anderloni, Andrea , Sharma, Prateek , Bhandari, Pradeep , Emura, Fabian

Mayo Clinic

United European Gastroenterology Journal | June 9, 2021 | Volume: 9 | Issue: 7 | Pages: 787-796

10.1002/ueg2.12103 | PMID 34102015 Get It

AbstractBackgroundThe novel Coronavirus (SARS‐CoV‐2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID‐19 vaccines, and a few more are going to be approved soon.MethodsSeveral different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non‐replicating viral vector vaccines, RNA based vaccines, DNA based vaccines).ResultsSince vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS‐CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients.ConclusionsThus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID‐19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination.
Medication‐overuse headache in patients with secondary headache disorders: Need for revision?
Ashina, Håkan , Ashina, Håkan , Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 9, 2021 | Volume: 61 | Issue: 5 | Pages: 790-791

10.1111/head.14108 | PMID 34105159 Get It

Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks
Schumacher, Julia , Gunter, Jeffrey L. , Przybelski, Scott A. , Graff‐Radford, Jonathan , Savica, Rodolfo , Senjem, Matthew L. , Jack, Clifford R. , Lowe, Val J. , Fields, Julie A. , Kremers, Walter K. , Petersen, Ronald C. , Graff‐Radford, Neill R. , Ferman, Tanis J. , Thomas, Alan , Kantarci, Kejal, Kantarci, Kejal , Graff-Radford, Jonathan , Boeve, Brad , Graff-Radford, Neill R , Jack, Clifford R , Thomas, Alan J , Taylor, John Paul , Senjem, Matthew L , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K , Jones, David T. , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Taylor, John‐Paul

Mayo Clinic

Brain | June 9, 2021 | Volume: 144 | Issue: 10 | Pages: 3212-3225

10.1093/brain/awab218 | PMID 34114602 Get It

Abstract Dementia with Lewy bodies (DLB) is neuropathologically defined by the presence of α-synuclein aggregates, but many DLB cases show concurrent Alzheimer’s disease pathology in the form of amyloid-β plaques and tau neurofibrillary tangles. The first objective of this study was to investigate the effect of Alzheimer’s disease co-pathology on functional network changes within the default mode network (DMN) in DLB. Second, we studied how the distribution of tau pathology measured with PET relates to functional connectivity in DLB. Twenty-seven DLB, 26 Alzheimer’s disease and 99 cognitively unimpaired participants (balanced on age and sex to the DLB group) underwent tau-PET with AV-1451 (flortaucipir), amyloid-β-PET with Pittsburgh compound-B (PiB) and resting-state functional MRI scans. The resing-state functional MRI data were used to assess functional connectivity within the posterior DMN. This was then correlated with overall cortical flortaucipir PET and PiB PET standardized uptake value ratio (SUVr). The strength of interregional functional connectivity was assessed using the Schaefer atlas. Tau-PET covariance was measured as the correlation in flortaucipir SUVr between any two regions across participants. The association between region-to-region functional connectivity and tau-PET covariance was assessed using linear regression. Additionally, we identified the region with highest and the region with lowest tau SUVrs (tau hot- and cold spots) and tested whether tau SUVr in all other brain regions was associated with the strength of functional connectivity to these tau hot and cold spots. A reduction in posterior DMN connectivity correlated with overall higher cortical tau- (r = −0.39, P = 0.04) and amyloid-PET uptake (r = −0.41, P = 0.03) in the DLB group, i.e. patients with DLB who have more concurrent Alzheimer’s disease pathology showed a more severe loss of DMN connectivity. Higher functional connectivity between regions was associated with higher tau covariance in cognitively unimpaired, Alzheimer’s disease and DLB. Furthermore, higher functional connectivity of a target region to the tau hotspot (i.e. inferior/medial temporal cortex) was related to higher flortaucipir SUVrs in the target region, whereas higher functional connectivity to the tau cold spot (i.e. sensory-motor cortex) was related to lower flortaucipir SUVr in the target region. Our findings suggest that a higher burden of Alzheimer’s disease co-pathology in patients with DLB is associated with more Alzheimer’s disease-like changes in functional connectivity. Furthermore, we found an association between the brain’s functional network architecture and the distribution of tau pathology that has recently been described in Alzheimer’s disease. We show that this relationship also exists in patients with DLB, indicating that similar mechanisms of connectivity-dependent occurrence of tau pathology might be at work in both diseases.
Exercise reduces circulating biomarkers of cellular senescence in humans
Englund, Davis A. , Sakamoto, Ayumi , Fritsche, Chad M., Heeren, Amanda A., Zhang, Xu , Kotajarvi, Brian R., Lecy, Denise R., Yousefzadeh, Matthew J. , Schafer, Marissa , White, Thomas A. , Atkinson, Elizabeth J. , Sakamoto, Ayumi E, Schafer, Marissa J, LeBrasseur, Nathan K , Schafer, Marissa J , Zhang, Xu , Sakamoto, Ayumi E., Fritsche, Chad, LeBrasseur, Nathan K. , Englund, Davis A.

Mayo Clinic

Aging Cell | June 9, 2021 | Volume: 20 | Issue: 7 | Pages: No page available

10.1111/acel.13415 | PMID 34101960 Get It

Abstract Cellular senescence has emerged as a significant and potentially tractable mechanism of aging and multiple aging‐related conditions. Biomarkers of senescent cell burden, including molecular signals in circulating immune cells and the abundance of circulating senescence‐related proteins, have been associated with chronological age and clinical parameters of biological age in humans. The extent to which senescence biomarkers are affected by interventions that enhance health and function has not yet been examined. Here, we report that a 12‐week structured exercise program drives significant improvements in several performance‐based and self‐reported measures of physical function in older adults. Impressively, the expression of key markers of the senescence program, including p16, p21, cGAS , and TNFα , were significantly lowered in CD3 + T cells in response to the intervention, as were the circulating concentrations of multiple senescence‐related proteins. Moreover, partial least squares discriminant analysis showed levels of senescence‐related proteins at baseline were predictive of changes in physical function in response to the exercise intervention. Our study provides first‐in‐human evidence that biomarkers of senescent cell burden are significantly lowered by a structured exercise program and predictive of the adaptive response to exercise.
Identification and Management of Traveler's Diarrhea
Levi, Miriam , Levi, Miriam E

Mayo Clinic

Journal of Midwifery & Women's Health | June 9, 2021 | Volume: 66 | Issue: 3 | Pages: 380-384

10.1111/jmwh.13256 | PMID 34101972 Get It

AbstractTraveler's diarrhea (TD) is a common occurrence when people travel to foreign countries and can affect individuals of all ages, including those who are pregnant. This clinical syndrome is caused by a variety of intestinal pathogens, and treatment is based on the acuity of the patient's symptoms. This case report describes the clinical presentation and management of a pregnant woman with a history of TD who requests an antibiotic prescription for the potential need of empiric self‐treatment of TD for an upcoming business trip outside of the United States. The clinical presentation of TD, differential diagnoses, treatment plan options, prevention recommendations, and empiric self‐treatment are reviewed. Current evidence‐based guidelines are discussed, and high‐risk conditions such as pregnancy are considered.
Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population-Based Analysis
Afifi, Ahmed , Elmehrath, Ahmed O. , Ruhban, Inas A., Gad, Mohamed M. , Al‐Husseini, Muneer J. , Bekaii‐Saab, Tanios , Saad, Anas M , Sonbol, Mohamad Bassam , Bekaii-Saab, Tanios S , Saad, Anas M.

Mayo Clinic

The Oncologist | June 8, 2021 | Volume: 26 | Issue: 9 | Pages: 733-739

10.1002/onco.13854 | PMID 34101294 Get It

Abstract Introduction Because of the improved colorectal cancer (CRC) survival in the U.S., patients may live long enough after CRC diagnosis to the point where non–cancer-related comorbidities may considerably impact their overall survival. In this study, we perform a long-term analysis of causes of death (CODs) following nonmetastatic CRC with respect to different demographic and tumor-related criteria. Materials and Methods We gained access to the Surveillance, Epidemiology, and End Results data to review patients diagnosed with nonmetastatic CRC during 2000–2015. We calculated standardized mortality ratios (SMRs) for each COD following CRC. SMRs represented the change of risk of a specific COD following CRC diagnoses when compared with the risk in the general U.S. population. Results We reviewed 302,345 patients, of whom 112,008 died during the study period. More deaths (68.3%) occurred within 5 years following nonmetastatic CRC diagnosis, with 76,486 deaths. CRC was the most common COD (51.4%) within 5 years of diagnosis followed by heart disease (15.2%) and other cancers (8.4%). As time passed after diagnosis, the number of CRC deaths decreased, and other noncancer causes increased to the point that after 10 years only 10.4% of deaths were attributed to CRC, 15.3% were attributed to other cancers, and 34.2% were secondary to heart disease. Conclusion Following nonmetastatic CRC diagnosis, most deaths remain secondary to CRC. Other causes, including other cancers and cardiovascular disease, represent a significant number of deaths, especially in the 5 years following initial CRC diagnosis. Our findings help guide counseling patients with CRC regarding future health risks. Implications for Practice Most common causes of death following nonmetastatic colorectal cancer (CRC) are heart diseases, other cancers, chronic obstructive pulmonary disease, and cerebrovascular diseases. Physicians should counsel patients regarding survivorship with cancer screening and focus on prevention of noncancer deaths. These findings should be considered by physicians who give care for survivors of nonmetastatic CRC.
Pharmacogenomics and Vaccine Development
Ovsyannikova, Inna G. , Kennedy, Richard B. , Kennedy, Richard , Poland, Gregory A.

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 8, 2021 | Volume: 110 | Issue: 3 | Pages: 546-548

10.1002/cpt.2288 | PMID 34097754 Get It

Analysis of Charges and Payments for Outpatient Arthroscopic Meniscectomy From 2005 to 2014: Hospital Reimbursement Increased Steadily as Surgeon Payments Declined
LaPrade, Matthew D. , Krych, Aaron J. , Krych, Aaron J , Camp, Christopher L. , Werner, Brian C.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 8, 2021 | Volume: 9 | Issue: 6 | Pages: No page available

10.1177/23259671211010482 | PMID 34164557 Get It

Background: Charge and reimbursement trends for arthroscopic partial meniscectomies among orthopaedic surgeons, anesthesiologists, and hospital/surgery centers have not been formally analyzed, even though meniscectomies are the most commonly performed orthopaedic surgery. Purpose: To analyze Medicare charge and reimbursement trends for surgeons, anesthesiologists, and hospital/surgery centers for outpatient arthroscopic partial meniscectomies performed in the United States. Study Design: Economic and decision analysis; Level of evidence, 4. Methods: We analyzed trends in surgeon, anesthesiologist, and hospital charges and reimbursements for outpatient isolated arthroscopic partial meniscectomies from 2005 to 2014. Current Procedural Terminology codes were used to capture charge and reimbursement information using the nationally representative 5% Medicare sample. National and regional trends for charge, reimbursement, and Charlson Comorbidity Index (CCI) were evaluated using linear regression analysis. Results: A total of 31,717 patients were analyzed in this study. Charges across all groups increased significantly ( P < .001) during the 10-year study period, with an increase of 18.4% ($2754-$3262) for surgeons, 85.5% ($802-$1480) for anesthesiologists, and 116.8% ($2743-$5947) for hospitals. Surgeon reimbursements declined by 15.5% ($504-$426; P = .072) during this period. Anesthesiologist and hospital reimbursements increased significantly during by 36.5% ($133-$182; P < .001) and 28.9% ($1540-$1984; P < .001) during the 10-year study period, respectively. The annual incidence of partial meniscectomies per 10,000 database patients decreased significantly from 18.3 to 15.6 over the course of the study (14.8% decrease; P = .009), while the CCI did not change significantly ( P = .798). Conclusion: Hospital and anesthesiologist Medicare reimbursements for outpatient arthroscopic partial meniscectomies increased significantly, while surgeon reimbursements decreased. In 2005, hospitals were reimbursed 205% more ($1540 vs $504) than surgeons, and by 2014, they were reimbursed 365% more ($1984 vs $426), indicating that the gap between hospital and surgeon reimbursement is rising. Improved understanding of charge and reimbursement trends represents an opportunity for key stakeholders to improve financial alignment across the field of orthopaedics.